Response to discontinuation of nucleos(t)ide analogue treatment in HBeAg-negative chronic hepatitis B: results from the Stop-NUC trial

F van Bömmel, K Stein, R Heyne, H Möller,J Petersen, P Buggisch,C Berg, C Werner, S Zeuzem, A Stallmach, A Herrmann, M Sprinzl, A Grambihler, E Schott, J Benckert, A Pathil-Warth,U von Arnim, V Keitel, J Trauth,KG Simon, C Trautwein, A Trein, D Hüppe, M Cornberg, F Lammert, P Ingilitz, R Zachoval, H Hinrichsen, A Zipprich, H Klinker,J Schulze zur Wiesch, O Brosteanu, A Schmiedeknecht, T Berg

DGVS Digital: BEST OF DGVSZeitschrift für Gastroenterologie（2020）

引用 0|浏览0

暂无评分

摘要

Background and aims Discontinuation of long-term suppression of HBV replication with nucleos(t)ide analogues (NUCs) can result in durable immune control of hepatitis B virus (HBV) replication in HBeAg negative patients. We have assessed the effect of NUC discontinuation in HBeAg negative patients in a prospective, multicenter, randomized trial (the Stop-NUC study).

查看译文

关键词

hepatitis,hbeag-negative,stop-nuc

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要